Humanized antibodies against human interferon-alpha
The present invention provides humanized anti-human IFN-α monoclonal antibodies useful for therapeutic applications in humans. Preferred antibodies are humanized versions of murine antibodies ACO-1 and ACO-2, as well as variants thereof.
1. A method of treating or ameliorating an IFN-α related condition or disease, said method comprising administering to a subject in need thereof a [prophylactically or] therapeutically effective amount of an antibody that binds human interferon-α and comprises a VH domain comprising SEQ ID NO:3 and a VL domain comprising SEQ ID NO:6.
2. The method of claim 1 , wherein said IFN-α related condition or disease is SLE.
3. The method of claim 1 , wherein said IFN-α related condition or disease is psoriasis.
4. A method of treating or ameliorating an IFN-α related condition or disease, said method comprising administering to a subject in need thereof a [prophylactically or] therapeutically effective amount of an antibody comprising at least one light chain that comprises the CDRs:
V L 1 having the amino acid sequence of SEQ ID NO:18;
V L 2 having the amino acid sequence of SEQ ID NO:19; and
V L 3 having the amino acid sequence of SEQ ID NO:20; and at least one heavy chain that comprises the CDRs:
V H 1 having the amino acid sequence of SEQ ID NO:15;
V H 2 having the amino acid sequence of SEQ ID NO:21; and
V H 3 having the amino acid sequence of SEQ ID NO:17.
5. The method of claim 4 , wherein said IFN-α related condition or disease is SLE.
6. The method of claim 4 , wherein said IFN-α related condition or disease is psoriasis.
7. The method of claim 1 , wherein said IFN-α related condition or disease is type I diabetes.
8. The method of claim 4 , wherein said IFN-α related condition or disease is type I diabetes.
9. The method of claim 1 , wherein said antibody is an IgG4 isotype antibody.
10. The method of claim 4 , wherein said antibody is an IgG4 isotype antibody.